Phase II Study of Continuous Infusion Carboplatin and Topotecan in the Treamtment of Relapsed Acute Myelogenous Leukemia (AML)
OBJECTIVES: I. Determine the efficacy of a 5-day continuous infusion of carboplatin and
topotecan in patients with relapsed and refractory acute myelogenous leukemia (AML). II.
Assess the toxic effects of this treatment in these patients.
OUTLINE: Patients receive continuous intravenous infusions of topotecan and carboplatin for
5 days. Treatment repeats every 3-4 weeks during induction (two courses) and every 6-10
weeks during consolidation. No more than four courses of treatment are given. Patients are
followed every 6 months for 5 years.
PROJECTED ACCRUAL: Up to 38 patients will be accrued for this study within 1.5 years.
Primary Purpose: Treatment
Scott H. Kaufmann, MD, PhD
United States: Federal Government